Search

A double-blind study was made of the activity and tolerance of 400 mg Floctaphenine versus 400 mg Acetylsalicylic Acid (ASA) on ordinary random administration. 48 patients received Floctaphenine and 50 ASA. Menstruating women were included, but not children aged less than 12 yr. Periodontitis, pulpitis, abscesses, extractions and dysodontiasis were the most frequently represented sources of pain. Subjects completing the study were divided into groups: those already treated with other analgesics in the previous 24 hr, those with uninterrupted pain, those with attacks of pain, those for whom one administration was sufficient, menstruating women. Account was also taken of the effect of treatment before or after meals, and the influence of a simultaneously administered antibiotic (the same one in each case). Statistical assessment showed that both drugs were analgesic, but that Floctaphenine was significantly (P < 0.01) better than ASA. The same was true with regard to latency time, duration of the effect, clinical assessment, need for support from other analgesics. The antibiotic appeared to have no appreciable influence of the activity of the two drugs, nor did the time of administration (before or after meals). Much the same picture was apparent in each group. Menstrual status was devoid of influence, though it cannot be stated with equal certainty that whether secondary effects were more frequent. Floctaphenine was very well tolerated. There were 4 somewhat doubtful cases of somnolence (8.33%). It was not certain, in fact, whether this was not an outcome of the relief from pain. ASA was accompanied by stomach pain in 9 cases (18%). This was much more common when it was taken on an empty stomach.

The analgesic activity and tolerance of a new non-narcotic synthetic analgesic derive from quinoline has been experimented in a double blind study. Phloctaphenin (200 mg) was compared with 200 mg of Acetylsalicylic acid (ASA). Administration of the drug was randomized: 41 patients received Phloctaphenin and 37 ASA. In addition to normal patients, the study also included menstruating women and, after paediatric check-up, children (i.e. under-12's). The conditions treated included periodontitis, pulpitis, abscesses, caries (with extraction), dysodontiasis and traumas. Patients were subdivided into groups (already treated with analgesics in the previous 24 h, not treated in the previous 24 h, affected by continuous pain, affected by fits of pain, subjects in whom a single drug administration was sufficient, patients in their menstrual period). Account was also taken of the outcome of treatment in relation to meals and of the influence of the association of an antibiotic (always the same). The study showed that both drugs possess analgesic activity but that of Phloctaphenin is statistically superior (almost always highly significant, i.e. P < 0.01) compared to ASA. The same applies to latency and the duration of the effect, the clinical judgment ad the need to administered other drugs. Association with the antibiotic has no influence whatever as might have been presumed considering the period of administration and the times of assessing the pain killing action of the two drugs. Administration before or after meals was irrelevant for both drugs. Statistical study of individual groups confirmed these results. From the viewpoint of side-effects, Phloctaphenin is better tolerated: with this new analgesic, in effect, only 2 debatable cases (4.87%) of side-effects (somnolence) were observed while 6 of the patients treated with ASA (16.20%) presented side-effects: 3 cases of gastric pyrosis (8.10%) before meals and 3 cases (8.10%) of hyperhydrosis after meals.

The clinical results obtained with phloctaphenin in an "open" study comprising cases of real neuralgia and spinal radicular pain syndromes and in a "double-blind" study comparing the preparation with a placebo, and involving algico-vasomotor syndromes of the face, are reported. The results obtained confirm the antalgic power of phloctaphenin for by the third day, subacute or chronic pain syndromes already presented a significant improvement in simptomatology, while in algico-vasomotor syndromes of the face, the treatment proved effective in eliminating pain attacks.